Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00180466 · ClinicalTrials.gov registry record
PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 697
- Enrollment target
NCT00180466: Completed study, sponsored by Abbott Medical Devices.
NCT00180466 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 697 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00180466 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 697 participants
- Enrollment target
Study Summary
PROSPECT is a multi-center prospective registry of Acute Coronary Syndromes (ACS) patients with single or double vessel coronary artery disease. Approximately 700 patients with ACS will be enrolled into the study at sites in the United States and European Union.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 697 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-07 |
What the finished NCT00180466 record still lists
NCT00180466 is an observational study that tracks outcomes without assigning an intervention. The registered 697 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00180466 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00180466 about?
NCT00180466 is a clinical study titled "PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions". PROSPECT is a multi-center prospective registry of Acute Coronary Syndromes (ACS) patients with single or double vessel coronary artery disease. Approximately 700 patients with ACS will be enrolled into the study at sites in the United States and European Union.
What is the current status of trial NCT00180466?
This trial is currently completed. The enrollment target is 697 participants. The study started on 2004-10. Estimated completion is 2009-07.
Who is sponsoring clinical trial NCT00180466?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03136094 · 698 participants · NA
Suicide in Urban Natives: Detection and Networks to Combat Events
- NCT04928846 · 698 participants · Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- NCT05943535 · 698 participants · Phase 3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- NCT07187115 · 699 participants · NA
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia